Why dividend stocks still matter in a volatile market
Markets lurch. Crypto crashes. Tech stocks get vaporized after one bad earnings call. And yet—some investors sleep just fine. Why? Because their portfolios drip cash every quarter. Dividends. Not flashy. Not viral. But powerful. They’re like rent from your money. You plant capital, and instead of waiting decades to sell high, you collect income now. That changes everything. Especially when inflation gnaws at purchasing power. A 3% yield isn’t impressive on paper—until you realize Treasuries are yielding 4% with zero growth. But dividend growers? They’ve raised payouts for 10, 20, even 60 years straight. The Dividend Kings and Aristocrats aren’t myths. They’re real, and they’re trading on the NYSE right now. Still, not all payouts are safe. Some firms borrow to fund dividends. Others cut when profits dip. The thing is, you can’t just chase yield like it’s a bargain at Costco. Dig deeper. Look at payout ratios. Study free cash flow. Ask: is this company printing money or pretending to?
And that brings us to a dirty secret: high yield often signals distress. If a stock yields 8%, ask why. Maybe it’s a REIT with aging properties. Or a telecom drowning in debt. Or—worse—a firm that’s about to slash its dividend. I am convinced that yield above 6% should set off alarms. Not always a red flag, but close enough to smell smoke.
How to spot a truly strong dividend payer
Free cash flow: the real engine behind dividends
You can fake earnings with accounting tricks. You can’t fake cash. Free cash flow—that’s revenue left after capital expenditures—is what actually funds dividends. No cash? No real dividend strength. Take AT&T. They paid $0.52 per quarter in 2021. Then slashed it to $0.27. Why? Debt load was crushing. Cash flow couldn’t keep up. The dividend wasn’t backed by earnings—it was backed by borrowing. And when the music stopped, shareholders got burned. Compare that to Johnson & Johnson. In 2023, they generated $20.4 billion in free cash flow. Dividend payout? $10.7 billion. Payout ratio: 52%. Sustainable. Breathing room. Room to grow. That’s the kind of math you want.
Dividend growth history: proof of commitment
Some companies pay dividends. The best ones grow them. Johnson & Johnson? 61 years of consecutive increases. Procter & Gamble? 67. Coca-Cola? 62. That’s not luck. It’s culture. It’s management teams that treat dividend growth like a sacred promise. But—and this is where people don’t think about this enough—not all increases are equal. A 1% bump isn't growth. It’s maintenance. Look for 5%+ annual hikes over the past decade. That signals pricing power, margin resilience, and real earnings momentum. A company raising dividends in line with inflation? Fine. One beating inflation by 3 percentage points? That’s wealth preservation.
Payout ratio: the warning light on the dashboard
Simple rule: if a company pays out more in dividends than it earns in net income, trouble looms. Same goes for free cash flow. A payout ratio above 80%? Red flag. 60% or below? Much safer. Altria, for instance, paid out $4.3 billion in dividends in 2023. Net income: $6.1 billion. Ratio: 71%. A bit high, sure, but tobacco margins are monstrous—80% gross margins let them absorb pressure. Verizon? Payout ratio based on free cash flow was 64% in 2023. Not ideal, but better than 2021, when it hit 98%. They’re improving. That said, if a firm’s ratio creeps toward 90% while debt rises? Run.
The 5 best dividend stocks worth owning today
Johnson & Johnson (JNJ): stability you can count on
Healthcare. Consumer products. Med-tech. J&J does it all. And through recessions, pandemics, even lawsuits, they’ve never cut the dividend. They’ve raised it for over six decades. Yield sits at 3.4%—not jaw-dropping, but reliable. What makes JNJ special? Diversification. One division falters, others compensate. Hip implants face litigation? Tide bottles still fly off shelves. Plus, post-2023 split (Kenvue spun off), the core company is leaner, more focused on high-margin medical devices. Payout ratio: 52%. Free cash flow: rock solid. This isn’t a stock to get rich quick. It’s a fortress. You buy it and forget it—except for the check that arrives every three months.
Procter & Gamble (PG): the quiet giant of consumer staples
They own 25 billion-dollar brands. Tide. Pampers. Gillette. Crest. You’ve used at least three of them this week. PG’s products are non-negotiable in most households. That resilience shows in the numbers: dividend increased every year since 1957. Yield? 2.4%. Modest. But with 67 years of hikes, compounding does the heavy lifting. Inflation hits? PG raises prices. Input costs surge? They absorb or pass through. Their margins have held between 23% and 26% for a decade. And because consumers aren’t ditching toothpaste or diapers, revenue barely flinches in downturns. The stock trades at 26x earnings—pricy? Maybe. But you’re not just buying earnings. You’re buying predictability. And in a world where nothing feels predictable, that’s worth something.
AbbVie (ABBV): biotech power with a fat yield
Here’s the irony: a biotech stock yielding 4.2%. That’s rare. Biotechs burn cash. AbbVie prints it. Thanks to Humira—the best-selling drug in history until biosimilars hit. Even now, with U.S. exclusivity gone, international sales and new drugs like Skyrizi and Rinvoq are filling the gap. Skyrizi revenue jumped 38% in 2023. Rinvoq up 45%. Free cash flow: $17.2 billion. Dividend payout: $13.1 billion. Ratio: 76%. High, but not reckless—growth is real. And unlike many dividend payers, AbbVie isn’t resting. They bought Allergan, then Kodiak Sciences. Pipeline’s deep. Yes, Humira dependence was a risk. We’re far from it now. This is not your grandfather’s pharma stock. It’s sharper. Hungrier. And it pays you well while it executes.
Verizon (VZ): telecom anchor with turnaround potential
Yield: 6.3%. One of the highest on the S&P 500. But is it safe? That’s the million-dollar question. Verizon’s had a rough few years. Fiber overbuilds. 5G costs. Management missteps. Free cash flow dipped. Dividend looked shaky. But—and this is key—they didn’t cut. Instead, they sold non-core assets, streamlined operations, and prioritized cash flow. 2023 saw FCF climb to $30 billion. Payout ratio improved. Debt down. Plus, they’re finally gaining wireless subscribers after years of losses. Is it back to glory? Not yet. But the bleeding stopped. And if 5G drives new revenue—streaming, IoT, enterprise services—Verizon could surprise. For income investors, it’s a calculated bet: high yield plus potential rebound. Just don’t expect miracles overnight.
Altria (MO): the contrarian play that keeps paying
Tobacco? In 2024? Seriously? Hear me out. Smoking rates are falling. No debate. But Altria’s not waiting to die. They’ve pivoted—Juul (failed), but now investing in oral nicotine (Zyn). Zyn sales up over 60% in 2023. And while cigarette volumes drop 4% yearly, pricing power offsets it. Marlboro price increased 12% last year. Margins? Still above 80%. Free cash flow: $8.3 billion. Dividend: $5.1 billion. Yield: 9.4%. Yes, 9.4%. But regulation looms. FDA crackdowns? Possible. Litigation? Ongoing. So why own it? Because the payout is covered, the dividend’s been raised for 55 years, and the stock yields so much you’re paid handsomely to wait. Just know what you’re buying: a high-yield, high-risk, slowly shrinking business. But one that’s not dead yet.
Dividend kings vs. high yield traps: which should you pick?
The Dividend Aristocrats (S&P 500 firms with 25+ years of increases) have beaten the broader index over the past 30 years—8.9% annual return vs. 7.3%. That’s real outperformance. But here’s the catch: they’re expensive. P/E ratios often above 20. And in a growth-starved market, they get bid up. High yielders like Altria or Verizon? Often out of favor. Beat-up. But that discount comes with risk. So which wins? I find this overrated: the idea that you must choose one or the other. Why not both? Allocate a core holding to JNJ or PG—stable, growing payouts. Then take a smaller, tactical position in higher-yield names for income boost. Balance matters. Because chasing 8% yield with weak fundamentals is like eating candy for dinner. Tastes good. Makes you sick later.
Frequently Asked Questions
Are high dividend stocks safe during a recession?
Generally, yes—especially in consumer staples, healthcare, and utilities. People still buy toothpaste, medicine, and electricity when times are tough. JNJ, PG, and MO all maintained or raised dividends during the 2008 crash. But not all high-yield stocks are recession-proof. Real estate and energy trusts often cut when cash flow dries up. So sector matters more than yield alone.
How often do these companies pay dividends?
All five—JNJ, PG, ABBV, VZ, MO—pay quarterly. That’s standard for U.S. equities. You’ll get a check every three months, usually in February, May, August, and November. Automatic reinvestment? Most brokers offer DRIPs (Dividend Reinvestment Plans), so you can buy more shares without lifting a finger.
Can a dividend stock still lose value?
Of course. Dividends don’t protect against price drops. Verizon yielded 6% in 2022—and still fell 20% that year. High yield can’t save you from bad sentiment, poor execution, or industry decline. You’re paid to wait, but capital losses can erase gains. The key? Focus on total return: income plus price appreciation. Not yield alone.
The Bottom Line
There’s no such thing as a perfect dividend stock. JNJ is safe but slow. ABBV grows fast but carries drug-pipeline risk. MO pays a king’s ransom in yield but faces existential threats. PG is reliable—maybe too reliable. VZ offers value, if you believe the turnaround. The best approach? Mix. Balance safety with yield. Prioritize cash flow over promises. And remember: dividends are a tool, not a magic spell. They won’t rescue a bad investment. But in the right hands—paired with patience and research—they can quietly build wealth over decades. Honestly, it is unclear what the market will do next year. But one thing’s certain: these five will keep writing checks. Whether you’re ready to collect them is up to you.